Journals / Abant Tıp Dergisi / 2022 / Cilt: 11 - Sayı: 2

The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats

Sıçanlarda Bupropion ve Vareniklinin Morfin Yoksunluğu Sendromu Üzerine Etkileri

Pages
231–242
Publication Date
2022-08-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Co-administration of varenicline with morphine was found to be effective on withdrawal symptoms such as bupropion, but had no effect on weight loss.Conclusion: These outcomes provide preliminary data which show that bupropion and varenicline can be used as a candidate drugs to attenuate morphine withdrawal symptoms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Opioid dependence is a chronic complicated disorder characterized by relapse and remission.
📊
Key Findings & Data:The purpose of the present study was to investigate the effect of anti-addictive drugs such as bupropion and varenicline on morphine dependence and naloxone precipitated withdrawal syndrome in a rat model.Materials and Methods: To assess the physical dependence of morphine, adult male Wistar rats were administered intraperitoneally (i.p.) increasing doses of morphine twice daily for 5 days, 4 hours after a single dose of morphine on day 6, and 15 minutes before subcutaneous (s.c.) naloxone (2 mg/kg, s.c.) administration to elicit withdrawal symptoms.
💡
Conclusion & Impact:Co-administration of varenicline with morphine was found to be effective on withdrawal symptoms such as bupropion, but had no effect on weight loss.Conclusion: These outcomes provide preliminary data which show that bupropion and varenicline can be used as a candidate drugs to attenuate morphine withdrawal symptoms.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Morfin · Bupropion · Vareniklin

Abstract

Objective: Opioid dependence is a chronic complicated disorder characterized by relapse and remission. Chronic administration of morphine causes symptoms of physical and psychological dependence. The purpose of the present study was to investigate the effect of anti-addictive drugs such as bupropion and varenicline on morphine dependence and naloxone precipitated withdrawal syndrome in a rat model.Materials and Methods: To assess the physical dependence of morphine, adult male Wistar rats were administered intraperitoneally (i.p.) increasing doses of morphine twice daily for 5 days, 4 hours after a single dose of morphine on day 6, and 15 minutes before subcutaneous (s.c.) naloxone (2 mg/kg, s.c.) administration to elicit withdrawal symptoms. Physical dependence was evaluated by injecting bupropion (5, 10, and 20 mg/kg, i.p.) and varenicline (0.5. 1, and 2 mg/kg, s.c.) for 15 minutes.Results: The morphine-dependent rats more significantly demonstrated withdrawal symptoms than naive control rats. The results elucidated that administration of bupropion and varenicline during induction of morphine dependence attenuated the most of the severity of withdrawal symptoms. Co-administration of bupropion with morphine reduced withdrawal symptoms such as jumping, wet dog shaking, weight loss and total withdrawal symptoms. Co-administration of varenicline with morphine was found to be effective on withdrawal symptoms such as bupropion, but had no effect on weight loss.Conclusion: These outcomes provide preliminary data which show that bupropion and varenicline can be used as a candidate drugs to attenuate morphine withdrawal symptoms.

Özet

Amaç: Opioid bağımlılığı, nüks ve remisyon ile karakterize kronik ve karmaşık bir hastalıktır. Kronik morfin uygulaması, fiziksel ve psikolojik bağımlılık semptomlarına neden olur. Bu çalışmanın amacı, bupropion ve vareniklin gibi anti-bağımlılık ilaçlarının morfin bağımlılığı ve nalokson ile hızlanırılmış yoksunluk sendromu üzerindeki etkisini sıçan modelinde araştırmaktı.Gereç ve Yöntemler: Morfine bağlı fiziksel bağımlılığı değerlendirmek için, yetişkin erkek Wistar sıçanlarına 5 gün boyunca günde iki kez artan dozlarda morfin intraperitoneal (i.p.) uygulandı. 6. günde tek doz morfin uygulamasından 4 saat sonra yoksunluk semptomlarını ortaya çıkarmak için subkutan (s.c.) nalokson (2 mg/kg, s.c.) uygulaması yapıldı. Fiziksel bağımlılık, 15 dakika süreyle intraperitoneal (i.p.) bupropion (5, 10 ve 20 mg/kg, i.p.) ve vareniklin (0,5, 1 ve 2 mg/kg, s.c) verilerek değerlendirildi.Bulgular: Morfin gurubunda kontrol grubuna göre önemli ölçüde yoksunluk semptomları görüldü. Sonuçlar, morfin bağımlılığının indüklenmesi sırasında bupropion ve vareniklin uygulamasının, yoksunluk semptomlarının şiddetinin çoğunu azalttığını gösterdi. Bupropionun birlikte uygulanması, sıçrama, ıslak köpek silkelenmesi, kilo kaybı ve toplam yoksunluk semptomlarını azaltmıştır. Vareniklinin birlikte uygulanmasının bupropion gibi yoksunluk semptomları üzerinde etkili olduğu, ancak kilo kaybı üzerinde etkisi olmadığı saptandı.Sonuç: Bu sonuçlar, bupropion ve vareniklinin morfininin yoksunluk semptomlarını hafifletmek için aday ilaçlar olarak kullanılabileceğine dair ön veriler sağlamaktadır.

🔖

Cite This Article

YUNUSOĞLU, O., KÖSE, Ç., SHAHZADİ, A., ÖZYAZGAN, S., DEMİR, B., ÖNAL, B., AKKAN, A. G. (2022). The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats. Abant Tıp Dergisi, Cilt: 11 - Sayı: 2, 231–242. https://ajindex.com/articles/448485

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. PERGOLIZZI J. V., JR., RAFFA R. B., ROSENBLATT M. H. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management, Journal of clinical pharmacy and therapeutics 2020: 45: 892-903
  2. CANAMO L. J., TRONCO N. B. Clinical Opioid Withdrawal Scale (COWS): Implementation and Outcomes, Critical care nursing quarterly 2019: 42: 222-226
  3. YUNUSOĞLU O. Rewarding effect of ethanol-induced conditioned place preference in mice: Effect of the monoterpenoid linalool, Alcohol (Fayetteville, NY) 2022: 98: 55-63
  4. WANG S. Historical Review: Opiate Addiction and Opioid Receptors, Cell transplantation 2019: 28: 233-238
  5. SRIVASTAVA A. B., MARIANI J. J., LEVIN F. R. New directions in the treatment of opioid withdrawal, Lancet (London, England) 2020: 395: 1938-1948
  6. BELL J., STRANG J. Medication Treatment of Opioid Use Disorder, Biological psychiatry 2020: 87: 82-88
  7. ALLAHVERDIYEV O., TÜRKMEN A. Z., NURTEN A., SEHIRLI I., ENGINAR N. Spontaneous withdrawal in intermittent morphine administration in rats and mice: effect of clonidine coadministration and sex-related differences, Turkish journal of medical sciences 2015: 45: 1380-1389
  8. LISTOS J., ŁUPINA M., TALAREK S., MAZUR A., ORZELSKA-GÓRKA J., KOTLIŃSKA J. The Mechanisms Involved in Morphine Addiction: An Overview, International journal of molecular sciences 2019: 20
  9. MAMALIGAS A. A., CAI Y., FORD C. P. Nicotinic and opioid receptor regulation of striatal dopamine D2-receptor mediated transmission, Scientific reports 2016: 6: 37834
  10. ISE Y., NARITA M., NAGASE H., SUZUKI T. Modulation of kappa-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats, Neuroscience letters 2002: 323: 164-166
  11. YAMAMOTO A., KIGUCHI N., KOBAYASHI Y., MAEDA T., UENO K., YAMAMOTO C. et al. Pharmacological relationship between nicotinic and opioid systems in analgesia and corticosterone elevation, Life sciences 2011: 89: 956-961
  12. REZAYOF A., ZATALI H., HAERI-ROHANI A., ZARRINDAST M. R. Dorsal hippocampal muscarinic and nicotinic receptors are involved in mediating morphine reward, Behavioural brain research 2006: 166: 281-290
  13. DAVENPORT K. E., HOUDI A. A., VAN LOON G. R. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain, Neuroscience letters 1990: 113: 40-46
  14. ISOLA R., ZHANG H., TEJWANI G. A., NEFF N. H., HADJ